Bodey G P, Yeo E, Ho D H, Rolston K, LeBlanc B
Clin Pharmacol Ther. 1985 Aug;38(2):134-9. doi: 10.1038/clpt.1985.149.
Ticarcillin (4 gm) and clavulanic acid (0.1 gm) were simultaneously administered as timentin to patients with cancer as therapy for infections. The pharmacokinetics of both ticarcillin and clavulanic acid were studied in 15 patients after 30-minute and 2-hour intravenous infusions. The mean (+/- SD) ticarcillin plasma peak concentrations after the two infusions were 341 +/- 76 and 210 +/- 60 micrograms/ml. The plasma terminal t1/2 values of ticarcillin were 80 +/- 32 and 56 +/- 12 minutes. The AUCs were 631 +/- 189 and 601 +/- 230 mg/L X hr. The volumes of distribution of the area were 15 +/- 5 and 21 +/- 7 L and total clearances were 115 +/- 36 and 127 +/- 54 ml/min. The corresponding values for clavulanic acid after the infusions are as follows: mean peak concentrations, 5 +/- 1 and 4 +/- 1 micrograms/ml; plasma terminal t1/2 values, 84 +/- 24 and 74 +/- 36 minutes; AUCs, 11 +/- 3 and 11 +/- 6 mg/L X hr; volumes of distribution of the area, 22 +/- 3 and 32 +/- 6 L; and total clearances, 170 +/- 58 and 175 +/- 68 ml/min.
替卡西林(4克)和克拉维酸(0.1克)作为特美汀同时给予癌症患者用于感染治疗。在15名患者中,于静脉输注30分钟和2小时后研究了替卡西林和克拉维酸的药代动力学。两次输注后替卡西林的平均(±标准差)血浆峰浓度分别为341±76和210±60微克/毫升。替卡西林的血浆末端t1/2值分别为80±32和56±12分钟。AUC分别为631±189和601±230毫克/升·小时。分布容积分别为15±5和21±7升,总清除率分别为115±36和127±54毫升/分钟。输注后克拉维酸的相应值如下:平均峰浓度分别为5±1和4±1微克/毫升;血浆末端t1/2值分别为84±24和74±36分钟;AUC分别为11±3和11±6毫克/升·小时;分布容积分别为22±3和32±6升;总清除率分别为170±58和175±68毫升/分钟。